Co-Founder; 13 years in speciality biopharma leadership roles from R&D to the executive. Novapeutics LLC is a biopharmaceutical company spun out from the University of Pennsylvania that aims to develop a first-in-class, oral curative therapeutic to reverse the course of diabetes by regenerating insulin-producing beta cells. Our approach utilizes small molecule therapeutics to disrupt menin and mixed-lineage leukaemia (MLL) proteins, known as a menin inhibitor, which enhancing endogenous beta cell regeneration in diabetes patients. Currently, with the support of the SBIR funding from NIH/NIDDK, we have identified promising novel menin inhibitors as our drug leads.
Share This Speaker